Trump, Congress And The Search For Common Ground On Drug Pricing
Executive Summary
Trump’s ideas for curbing drug pricing have support in Congress but not among those in power; Republican leaders, including the president-elect’s choice for HHS secretary, Tom Price, have long opposed government negotiation in Medicare.
You may also be interested in...
Finally, Drug Pricing Consensus: There's No 'Silver Bullet' For This Werewolf
All sides have resorted to the mythological phrase throughout the debate, and industry can only hope that the phase of the moon changes soon.
J&J Outlines Pricing Transparency Plan, Will Others Follow?
CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.